Petra: Saruparib In Solid Tumors With Brca1/2, Palb2 Or Rad51C/D Mutations

PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

PARPi for somatic BRCA1/2 and other DNA repair gene mutations in women with metastatic breast cancer

APOLLO: olaparib in pancreatic cancer with a BRCA1/2 or PALB2 mutation

Seminar Clips: PARP Inhibitors and BRRCA1/2 Cancers- Susan Domchek, MD | Stanford Cancer Institute

Stanford Cancer Institute

PARP inhibitory velaparib trialled in BRCA1/2 breast cancer

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastati...

PARP inhibitors: activity in BRCA1 versus BRCA2 altered mCRPC

TALAVE: induction talazoparib with PARP inhibition in breast cancer

PARP Inhibitor Olaparib Exceeds Expectations in BRCA+ Pancreatic Cancer Management

Targeted Oncology

Tripathy Discusses a Study of Talazoparib in BRCA-Mutated Advanced Breast Cancer

Targeted Oncology

Overcoming resistance to PARPi in BRCA1-deficient breast cancer with STING agonists

PARP Inhibitors gBRCA1/2-Mutated Pancreatic Cancer

PARP Inhibitors in BRCA1/2-mutated Patients in Prostate Cancer

Discover the relationship between PARP proteins & BRCA mutations in cancer development and treatment

Art of Healing Cancer

Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer

First-in-human trial of MEDI1191 plus durvalumab in patients with advanced solid tumors

Using Olaparib in gBRCA1/2+ Breast Cancer